N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 10, 2011, Pages 1403-1408

  Leiro Fernandez, Virginia ^a   Valverde, D ^b   Vazquez Gallardo R ^a   Botana Rial, M ^a   Constenla, L ^c   Agundez J A ^d   Fernandez Villar A ^a  

^a HOSPITAL XERAL CÍES   (Spain)

^b UNIVERSITY OF VIGO   (Spain)

^c UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^d UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

Acetilator status; Hepatotoxicity; Pharmacogenomics; Polymorphims; Tuberculosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ARYLAMINE ACETYLTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME POLYMORPHISM; ETHNIC DIFFERENCE; FEMALE; FOLLOW UP; GENE FREQUENCY; GENOTYPE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TUBERCULOSIS;

ADULT; ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DRUG-INDUCED LIVER INJURY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; ISONIAZID; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PHENOTYPE; POLYMORPHISM, GENETIC; PYRAZINAMIDE; RIFAMPIN; RISK ASSESSMENT; RISK FACTORS; TUBERCULOSIS;

EID: 80053210047     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.10.0648     Document Type: Article

References (29)

1. Global tuberculosis control: surveillance, planning, financing. WHO report 2005. WHO/HTM/TB/2005.349. Geneva, Switzerland: WHO, 2005.
2. Infectious Disease Society of America. Practice guidelines for the treatment of tuberculosis. Clin Infect Dis 2000; 31: 633-639.
3. American Thoracic Society. Hepatotoxicity of anti-tuberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-952.
4. Tostmann A, Boeree M J, Aarnoutse R E, De Lange W C, Van der Ven A J, Dekhuijzen R. Anti-tuberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastronterol Hepatol 2008; 23: 192-202. (Pubitemid 351257678)
5. Fernández-Villar A, Sopeña B, Vázquez R, et al. Isoniazid hepatotoxicity among drug users: the role of hepatitis C. Clin Infect Dis 2003; 36: 293-298. (Pubitemid 36169664)
6. Fernández-Villar A, Sopeña B, Fernández-Villar J, et al. The influence of risk factors in the severity of antituberculosis druginduced hepatotoxicity. Int J Tuberc Lung Dis 2004; 8: 1499-1505. (Pubitemid 40070258)
7. Sharma S K, Balamurugan A, Saha P K, Pandey R M, Mehra N K. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during anti-tuberculosis treatment. Am J Respir Crit Care Med 2002; 166: 916-919. (Pubitemid 35193218)
8. Sun F, Chen Y, Xiang Y, Zhan S. Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis druginduced liver injury: a meta-analysis. Int J Tuberc Lung Dis 2008; 12: 994-1002.
9. Bose P D, Sarma M P, Medhi S, et al. Role of polymorphic N-acetyl transferase 2 and cytochrome P4502E1 gene in anti-tuberculosis treatment-induced hepatitis. J Gastronterol Hepatol 2011; 26: 312-318.
10. Lee S W, Chung L S, Huang H H, et al. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J Tuberc Lung Dis 2010; 14: 622-626.
11. Bozok Çetintas V, Erer O F, Kosova B, et al. Determining the relation between N-acetyltransferase-2 acetylator phenotype and anti-tuberculosis drug induced hepatitis by molecular biologic tests. Tuberk Toraks 2008; 56: 81-86.
12. Higuchi N, Tahara N, Yanagihara K, et al. NAT2 6A, a haplotype of the N-acetylatransferase 2 gene, is an important biomarker for risk of anti-tuberculosis hepatotoxicity in Japanese patients with active tuberculosis. World J Gastronterol 2007; 13: 6003-6008. (Pubitemid 350252844)
13. Ohno M, Yamaguchi I, Yamamoto I, et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 2000; 4: 256-261. (Pubitemid 30151575)
14. Cho H J, Koh W J, Ryu Y J, et al. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drugi nduced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb) 2007; 87: 551-556.
15. Wang T, Yu H T, Wang W, et al. Genetic polymorphisms of cytochrome P450 and glutathione S-transferase associated with anti-tuberculosis drug-induced hepatotoxicity in Chinese tuberculosis patients. J Int Med Res 2010; 38: 977-986.
16. Chatterjee S, Lyle N, Mandal A, Kundu S. GSTT1 and GSTM1 gene deletions are not associated with hepatotoxicity caused by antitubercular drugs. J Clin Pharm Ther 2010; 35: 465-470.
17. Leiro V, Fernández-Villar A, Valverde D, et al. Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of anti-tuberculosis drug-induced hepatotoxicity in a Caucasian population. Liver Int 2008; 28: 835-839. (Pubitemid 351818646)
18. Kim S H, Kim S H, Yoon H J, et al. GSTT1 and GSTM1 null mutations and adverse reactions induced by anti-tuberculosis drugs in Koreans. Tuberculosis (Edinb) 2010; 90: 39-43.
19. World Health Organization. WHO ART adverse drug reaction terminology. Geneva, Switzerland: WHO Collaborating Center for Drug International Monitoring, 1979.
20. Bell D A, Taylor J A, Butler M A, et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African- Americans. Carcinogenesis 1993; 14: 1689-1692. (Pubitemid 23249380)
21. Stephen M, Donnelly P. A comparison of Bayesian methods for haplotype reconstruction. Am J Hum Genet 2003; 73: 1162-1169. (Pubitemid 37414228)
22. Agúndez J A, Golka K, Martínez S, Selinski S, Blaszkewicz M, García-Martín E. Unraveling ambiguous NAT2 genotyping data. Clin Chem 2008; 54: 1390-1394.
23. Agúndez J A, Martinez C, Olivera M, Ledesma M C, Ladero J M, Benitez J. Molecular analysis of the arylamine N-acetyltransferase polymorphism in a Spanish population. Clin Pharmacol Ther 1994; 56: 202-209. (Pubitemid 24274187)
24. Garte S, Gaspari L, Alexandrie A K, et al. Metabolic gene polymorphism in control populations. Cancer Epidemiol Biomarkers Prev 2001; 10: 1239-1248. (Pubitemid 34027754)
25. García-Martín E. Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms. Curr Drug Metab 2008; 9: 487-497. (Pubitemid 352034203)
26. Vatsis K P, Weber W W, Bell D A. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995; 5: 1-17.
27. Cascorbi I, Drakoulis N, Brockmöler J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995; 57: 581-592.
28. Abe M, Deguchi T, Suzuki T. The structure and characteristics of a fourth allele of polymorphic N-acetyltransferase gene found in the Japanese population. Biochem Biophys Res Comm 1993; 191: 811-816. (Pubitemid 23231562)
29. Lin H J, Han C H Y, Lin B K, Hardy S. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, Blacks, Hispanics and Whites: application to metabolic epidemiology. Am J Hum Genet 1993; 52: 827-834. (Pubitemid 23310153)